All News

laptop

New Research Demonstrates Impact of RISE Registry Data on Rheumatology Outcomes

ACR Press Release

New research presented at ACR Convergence 2025 highlights how the Rheumatology Informatics System for Effectiveness (RISE) registry—the nation’s largest collection of electronic health record data from rheumatology practices—is driving transformative improvements in quality, safety, and patient outcomes across rheumatic and musculoskeletal diseases.

Read Article
GLP-1.pink

GLP-1 Receptor Agonists: Impacts Beyond Metabolism?

Mrinalini Dey, MD

The GLP-1 story has been hard to miss this year, and at ACR Convergence, it’s clear that these drugs are starting to make real waves in rheumatology. Across multiple abstracts, investigators have used a large real-world dataset, the TriNetX network, to explore how GLP-1 receptor agonists (GLP-1RAs) might influence cardiovascular, renal and immune-mediated outcomes in our patients.

Read Article
Gout pills injection

New Gout Therapies Show Promise in Phase III Trials

ACR Press Release

At ACR Convergence 2025, the American College of Rheumatology’s annual meeting, researchers presented pivotal Phase III studies highlighting novel therapeutic options for patients with gout, particularly those with limited treatment choices or uncontrolled disease.

Read Article
pill,ASA,colchcine,small

Colchicine Ineffective in Long COVID

Jack Cush, MD

Management of long COVID has been perplexing with symptoms having functional and possibly inflammatory origins. Colchicine has been studied in long COVID and failed to improve functional capacity, respiratory function, or inflammatory markers. 

Read Article
RheumNow Podcast square

Bad Actor Cofactor (10.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.

Read Article
RheumNow Podcast square

Associations in Rheumatology (10.3.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.com.

Read Article
RheumNow Podcast square

Big Fat FDA Pink Slip (9.19.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com. Today we cover GLP-1 agonists, acupuncture, what JAKs won’t do & an FDA Pink Slip. 

Read Article
GLP-1 RA vs DPP4i & risk of rheumatic disease: propensity score matched cohort study using TriNetX 🔹 Lower incidence of OA, RA & gout w/ GLP-1 RA 🔹 No significant differences for PsA, SSc, axSpA, or SLE @RheumNow #ACR25 https://t.co/BIVw3ajrFZ

Links:

Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
#2660 In >8000 women, serum urate rose sharply during the menopausal transition, then plateaued after menopause. Hyperuricemia reached 4-5% post-menopause, up to 18% in obesity or low eGFR. Healthy body weight & kidney function pre-menopause may decrease HU later @RheumNow #ACR25 https://t.co/v6ai3lgAd2

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
In the epidemiology session on the final day of #ACR25, a large cohort study (>430k pts) showed that GLP-1 receptor agonists were linked to lower incidence of RA, gout & OA vs DPP-4 inhibitors. Adds to the growing case for GLP-1 benefits beyond glucose control. @RheumNow #2657

Mrinalini Dey DrMiniDey ( View Tweet)

Gut microbiome on Urate metabolism study- 1500 men and women. From 3 cohorts- Framingham, nurses health and men's lifestyle with blood and stool data Focused on 5 urate metbolizing genes Abst#2590 #ACR25 @RheumNow https://t.co/YxBb3WfcbB

Links:

Bella Mehta bella_mehta ( View Tweet)
Is MTX worth anything in GCA? METOGiA: MTX 52w vs TCZ 52w for GCA MTX didn’t achieve non-inferiority to TCZ, but: - clearly it does something - continue both >1y: after MTX/TCZ therapy ended, they ended up with same relapse-free survival, cumulative GC #ACR25 ABST0891 @RheumNow https://t.co/WvvkHKIXuQ

Links:

David Liew drdavidliew ( View Tweet)
From the plenary to posters, RheumNow is your companion for ACR Convergence 2025. Expect: • KOL videos • Clinical trial highlights • Daily faculty recaps • Live streaming #ACR25 #Rheumatology #ClinicalTrials https://t.co/zZAwYINmC2
Dr. John Cush RheumNow ( View Tweet)

Osteonecrosis: suspect with trauma, high-dose steroids, alcoholism, renal failure, transplantation, SLE, thrombotic states (e.g., sickle cell anemia, hemoglobinopathies), radiation injury, pancreatitis, gout, pregnancy, hyperlipidemia, & caisson disease (decompression sickness) https://t.co/y6iYd5fWZ2

Dr. John Cush RheumNow ( View Tweet)
Post hoc analysis of Gout (CARES) trial (rx w/ ULT) showed remission @ 1yr increased from 37% to 63% at yr 6. In 6 yrs, 59% achieved remission 1+ times. Remission was signif assoc w/ age, race, Hi Dz severity, comorbidities, and febuxostat treatment https://t.co/uTOkch8VW6 https://t.co/Ykc7JV6m7r

Links:

Dr. John Cush RheumNow ( View Tweet)
SUA levels & adverse health outcomes? Australian ASPREE trial of 11,878 older participants had baseline SUA measurements. SUA levels had NO ASSOC. w/ all-cause mortality, disability-free survival, CV Dz, MACE, cancer mortality, cognitive decline, or dementia. In females, low SUA https://t.co/VY6NJsetW9
Dr. John Cush RheumNow ( View Tweet)
Target trial emulation looked at CV (MACE) events in 18,120 propensity score–matched adults with gout starting allopurinol who were given NSAIDs or colchicine for prophylaxis. MACE & CV death were signif. higher w/ NSAIDs vs Colchicine (HRs of 1.56 and 2.50), respectively. https://t.co/0T8slmPBng
Dr. John Cush RheumNow ( View Tweet)
COLCHICORT Trial The COLCHICORT trial in acute calcium pyrophosphate (CPP) crystal arthritis patients showed that colchicine was inferior to prednisone treatment and that responses were also influenced by other factors. https://t.co/CC2yVRXbD5 https://t.co/ebLa3FUbGR

Links:

Dr. John Cush RheumNow ( View Tweet)
Gout: Highlights from APLAR 2025 Dr. Sheila Reyes, The Philippines, reports on highlights and takeaways from lectures on the treatment of gout from the APLAR 2025 Congress in Fukuoka, Japan. https://t.co/Fxd3MBUYrT https://t.co/gKjHlJXttT

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Binit Vaidya aptly poses this slide on the gout paradox: evidence-based T2T tx exist yet many still have uncontrolled dse. How can we close this gap? - address barriers to tx adherence - motivation - px education - multidisciplinary approach to px care @rheumnow #APLAR25 https://t.co/IEn9PMAxH5

Links:

sheila RHEUMarampa ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×